Abstract Details

Title Cerebrospinal fluid interleukine-8 to distinguish Guillain-Barré Syndrome from chronic inflammatory demyelinating polyneuropathy

Topic General Neurology

Presentation(s) General Neurology Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 003

Objective

To determine if cerebrospinal fluid interleukin-8 concentration can help to distinguish Guillain-Barré syndrome (GBS) from chronic inflammatory demyelinating polyneuropathy (CIDP) at the initial stage of the disease.

Background

GBS and CIDP can be difficult to distinguish at their early stage - conventional clinical and paraclinical exams - whereas their clinical evolution and treatment response differ. In our study we aimed to determine cerebrospinal fluid (CSF) concentration of interleukin-8 (IL-8) and to analyze its usefulness to differentiate GBS from CIDP.

Design/Methods We retrospectively measured IL-8 concentration (multiplex immunoassays) in the CSF of patients with GBS (n=45) and CIDP (n=30) followed at the University Hospitals of Geneva between 2010 and 2018. Diagnoses were established according to Brighton and European Federation of Neurological Societies/Peripheral Nerve Society criteria by a physician blinded to biological results. We compared IL-8 concentration results in GBS and CIDP patients.

Results CSF IL-8 concentration in GBS (median: 84 pg/ml) was higher than in CIDP (median: 41 pg/ml; p<0.001). Above an estimated cut-off value at 70 pg/ml for CSF IL-8 concentration (Youden index), patients were more likely to present GBS than CIDP (positive predictive value 96%). Among GBS subcategories, CSF IL-8 concentration was higher in acute inflammatory demyelinating polyneuropathy as opposed to axonal GBS phenotypes.

Conclusions CSF IL-8 levels can be used to differentiate GBS from CIDP.

Authors/Disclosures
Gautier Breville, MD PRESENTER	Dr. Breville has nothing to disclose.
	No disclosure on file
Patrice LaLive, MD	Dr. LaLive has nothing to disclose.

��ɫ��

��ɫ��